An observational study in Asthma, sponsored by Chiesi Pharma AB, Nordic. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Chiesi Pharma AB, Nordic (part of Chiesi Farmaceutici S.p.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2025, is one of 15 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 75th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Chiesi Farmaceutici S.p.A. · Sites in Bulgaria
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
Chiesi Farmaceutici S.p.A. · Sites in Argentina, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–75
Chiesi Slovenija, d.o.o. · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 24 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 97 across the 66 interventional studies, 300 across the 15 observational. Of the 69 that completed or were terminated, 13 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chiesi Pharma AB, Nordic, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
This is the only study on the registry with Chiesi Pharma AB, Nordic as lead sponsor.
2 of the studies in Asthma by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301736Chiesi Farmaceutici S.p.A.Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | 2027-06-03 |
| NCT06908421Chiesi Pharma AB, NordicEfficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI inhalers. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments.
The main questions it aims to answer are:
Participants will:
The study does not have a comparison group and all results will be compared to baseline.
Background and Rationale Asthma is a chronic inflammatory disease of the airways that affects millions of individuals worldwide. Despite the availability of effective inhaled medications, poor adherence and incorrect inhaler technique remain major barriers to optimal asthma control. Studies show that up to 86.7% of asthma patients make at least one inhaler technique error, and 30-40% demonstrate poor adherence to their prescribed medication. These factors contribute to worsened symptoms, increased healthcare utilization, and reduced quality of life.
The SiA® system, developed by Briota ApS, aims to address these challenges by integrating a smart inhaler cap (RespiPRO™) with a mobile application. This system provides real-time feedback on inhaler technique and adherence, allowing patients and healthcare providers to track progress and make necessary adjustments.
This study seeks to determine whether using the SiA® system alongside a pressurized metered dose inhaler (pMDI) therapy can lead to measurable improvements in medication adherence, inhalation technique, and asthma control. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by inadequate treatment caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments.
Study Design This is a prospective, single-arm observational study conducted at two hospitals in Denmark. It is designed to assess how the SiA® System impacts inhaler technique and medication adherence over a 12-month period.
Key Features of the Study Design:
Study Setting:
Data Collection Methods:
Data will be collected through multiple sources:
Technology Used in the Study:
Study Timeline:
Total Study Duration: 22 months, with individual patient follow-up lasting 12 months (52 weeks).
Patient Flow and Study Visits:
Screening and Baseline Visit (Week 0) - Study Enrolment
Interim Follow-up Visit (Week 12) - Progress Check
Repeat measurements:
Final Study Visit (Week 52) - End of Study
Potential Impact of the Study
This study aims to generate real-world evidence on how digital health interventions can improve asthma management. If successful, the SiA® System could:
Asthma patients above 18 years of age, with objectively verified diagnosis of asthma according to GINA, uncontrolled T2 inflammation (FeNO >25ppm) on BDP/FF/G inhalation treatment with prescribed rescue medication (SABA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treated with Trimbow 87/5/9 pMDI for >4 weeks before enrolment,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asthma patients above 18 years of age, with objectively verified diagnosis of asthma according to GINA, uncontrolled T2 inflammation (FeNO \>25ppm) on BDP/FF/G inhalation treatment with prescribed rescue medication (SABA).
To evaluate the impact of the SiA® platform on the level of the type 2 inflammation biomarker FeNO
To assess the impact of the study on the type 2 biomarker FeNO with a change from baseline of at least 20% will be considered clinically relevant. FeNO values will be presented as ppb. FeNO levels of \< 25 ppb, 25 - 50 ppb, \> 50 ppb, are considered low, medium, and high respectively.
Time frame: Change from baseline in FeNO at week 12 and 52.
To assess the impact of the SiA® platform on adherence to SITT and inhaler technique measure using the RespiPRO add-on module
Change in inhaler adherence measured as percentage of days covered and inhaler technique scores based an assessments of inhalation video recordings an data collected from the SiA® platform using a scoring system of 1-5, where 5 = Optimal technique; 4 = Poor technique with one critical error; 3 = Poor technique with two critical errors; ≤2 = Poor technique with three or more critical errors. The RespiPRO™ cannot monitor step 1 and 2, thus are these by default set to 1, hence the minimum inhaler technique scores achievable from RespiPRO™ is 2.
Time frame: Change in pMDI inhaler technique score and medication adherence score at week 12 and 52 compared to baseline.
To evaluate the impact of the SiA® platform on asthma control using Asthma Control Test
Asthma control will be assesed using Asthma Control Test (ACT), which is a patient self-administred tool for identifying those with poorly controlled asthma. A maximum score of 25 points indicates complete asthma control. A score between 20 and 25 represents well controlled asthma, while a score of 19 or below represents not well controlled asthma, and a score less than 16 indicates very poorly controlled asthma.
Time frame: Change in ACT scores from baseline at weeks 12 and 52
To evaluate the impact of the SiA® platform on health-related quality of life
To assess the impact of the study on Health-related Quality of Life (HR QoL) using Asthma Quality of Life Questionnaire (mini-AQLQ). The mini-AQLQ has 15 questions in the same domains as the original AQLQ (symptoms, activities, emotions and environment).
Time frame: Change in mini-AQLQ scores from baseline at weeks 12 and 52
To evaluate the impact of the SiA® platform on lung function measured by spirometry
Change in lung function parameters (change in mean FEV1, FEV1 %-predicted, FEV1/FVC ratio, FEF25-75) from baseline at weeks 12 and 52
Time frame: From baseline and at week 12 and 52.
To evaluate the impact of the SiA® platform on shifts in FeNO category
Change in FeNO category (low, intermediate, high) defined as (\< 25 ppb, 25 - 50 ppb, \> 50 ppb, respectively.
Time frame: Change from baseline at week 12 and 52.
To evaluate the impact of the SiA® platform on annualized exacerbations rates
Retrospective data from the past 12 months will gathered the number of moderate and severe exacerbations as defined by the American Thoracic Society/European Respiratory Society.
Time frame: Change in annualized exacerbation rates (moderate and severe) from baseline at week 52
o evaluate the impact of the SiA® platform on the use of rescue medication (SABA)
To assess the impact of the study intervention on use of rescue medication (SABA) measured as average puffs per day/week/month.
Time frame: Change from baseline (first 7 days after entering the study) in the use of rescue medication (SABA) at week 12 and 52).
Satisfaction and compliance with add-on device based on a customized survey
Satisfaction score at week 52 assessed using a customized questionnaire. The survey reports on 9 question related to the satisfaction with SiA® platform. Each of the 9 question can be given a score from 1-5. where 1 = very difficult/dissatisfied, 3 = neutral, and 5 = very easy/satisfied.
Time frame: at week 52.
Plan to share: Undecided
Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.
Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 24 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.